QULIPTA dose modifications1
Dosing modifications should be considered for patients with hepatic and renal impairment and concomitant use of specific drugs.
Adapted from the QULIPTA Product Monograph.
Safety information
Click here for additional safety information and for a link to the Product Monograph discussing:
●Relevant warnings and precautions regarding patients with severe hepatic impairment, driving and operating machinery, pregnant and nursing women, and geriatrics.
●Conditions of clinical use, adverse reaction, drug interactions and dosing instructions.
Reference:
1. QULIPTA Product Monograph. AbbVie Corporation.
CrCl: creatinine clearance; OATP: organic-anion-transporting polypeptides.
* Examples include itraconazole, ketoconazole, clarithromycin.
† Examples include ciprofloxacin, fluconazole, fluvoxamine, grapefruit juice, cimetidine, esomeprazole.
‡ Examples include multiple-dose rifampicin, carbamazepine, phenytoin, St. John’s wort, efavirenz, etravirine.
§ Examples include topiramate, armodafinil, rufinamide.
¶ Examples include cyclosporine, single-dose rifampicin.
For more information
For any questions related to QULIPTA, you can contact AbbVie Medical Information at 1 844 241-5011.
QULIPTA and its design are trademarks of Allergan Pharmaceuticals International Limited, an AbbVie company, used under license by AbbVie Corporation.
© 2024 AbbVie. All rights reserved.
CrCl: creatinine clearance; OATP: organic-anion-transporting polypeptides.
* Examples include itraconazole, ketoconazole, clarithromycin.
† Examples include ciprofloxacin, fluconazole, fluvoxamine, grapefruit juice, cimetidine, esomeprazole.
‡ Examples include multiple-dose rifampicin, carbamazepine, phenytoin, St. John’s wort, efavirenz, etravirine.
§ Examples include topiramate, armodafinil, rufinamide.
¶ Examples include cyclosporine, single-dose rifampicin.
For more information
For any questions related to QULIPTA, you can contact AbbVie Medical Information at
1 888 241-5011.
QULIPTA and its design are trademarks of Allergan Pharmaceuticals International Limited, an AbbVie company, used under license by AbbVie Corporation.
© 2024 AbbVie. All rights reserved.
CA-QLP-240063A / OC24